Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

By LabMedica International staff writers
Posted on 11 Aug 2026

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. More...

Computed tomography (CT) detects small nodules but can flag benign findings, adding patient risk and cost. Liquid biopsies offer a noninvasive alternative but typically depend on DNA sequencing and complex analytics. A new study shows a sequencing-free blood test on a chip can classify lung cancer using chemical fingerprints in cell-free DNA.

Tel Aviv University scientists developed a method called sequencing-free on‑chip detection by fluorescent enzymatic profiling of cell‑free DNA (cfDNA) methylation. After extracting cfDNA from blood, the fragments are labeled with a light‑emitting marker and hybridized to a custom DNA chip. An optical scanner reads the chip, and light‑emission patterns are computationally analyzed to identify a malignancy‑specific chemical signature, eliminating the need for DNA sequencing.

In a study of 103 participants, the cohort comprised 51 individuals with lung cancer and 52 healthy controls. Following a training phase, the team derived a signature spanning 170 genomic regions and evaluated it in a separate validation set using blinded analysis. The approach also differentiated the two predominant histologies—adenocarcinoma and squamous cell carcinoma—based on distinct cfDNA signatures.

For patients with stage 2-4 disease, the test achieved 93.1% sensitivity and 90.3% specificity. Beyond diagnosis, serial testing reflected treatment response: fingerprints in responders shifted toward a healthy profile, while non‑responders showed no meaningful change, mirroring imaging results. The investigators emphasized that these monitoring findings are preliminary and require confirmation in larger studies.

The work, published in npj Precision Oncology, involved collaborators from JaxBio Technologies, Bnai Zion Medical Center, and Sheba Medical Center. The researchers cited simplicity, low cost, and rapid turnaround as key advantages; current processing takes two to three days at an estimated cost of about $60 per sample. They indicated that the assay could complement imaging, support earlier diagnosis of lung cancer, and help monitor treatment effectiveness.

“Our goal is to make blood tests for cancer diagnosis more accessible, simpler and less expensive without compromising accuracy. We have developed a new approach that does not require genetic sequencing but instead identifies the tumor's chemical 'fingerprint' with light, using a technology that can be implemented in standard clinical laboratories. This is a significant step toward developing a tool that can complement imaging tests and help physicians diagnose lung cancer and monitor treatment effectiveness,” said Yuval Ebenstein, professor at Tel Aviv University’s School of Chemistry, Department of Biomedical Engineering, and the Zimin Institute.

Related Links
Tel Aviv University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Silver Member
Vitamin D Assay
EZ Vitamin D Assay
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.